Literature DB >> 29851742

The Direct and Indirect Costs Associated With Overactive Bladder Within a Commercially-Insured Population in the United States.

Emily Durden1, David Walker, Stephani Gray, Robert Fowler, Paul Juneau, Katherine Gooch.   

Abstract

OBJECTIVE: To quantify the burden associated with overactive bladder (OAB) within a commercially-insured United States (US) population.
METHODS: Adults with OAB identified from the MarketScan databases (2008 to 2013) were propensity score matched 1:1 to non-OAB controls. Per-patient-per-month (PPPM) direct healthcare costs, and indirect costs attributable to workplace absence and short-term disability (STD), were estimated.
RESULTS: Adjusted PPPM healthcare costs were higher for OAB patients than matched controls for both direct costs ($3003 vs $1123; P < 0.0001) and indirect costs due to STD ($114 vs $98; P < 0.05). There was no difference in the indirect costs due to absence between the OAB cases and controls.
CONCLUSIONS: The direct healthcare costs of OAB patients are substantial. Additional research is needed to quantify the impact of OAB on workplace productivity. Improved management of OAB symptoms may reduce costs and enhance patient quality of life.

Entities:  

Mesh:

Year:  2018        PMID: 29851742     DOI: 10.1097/JOM.0000000000001367

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  2 in total

1.  Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study.

Authors:  Shelagh M Szabo; Katherine Gooch; Carol Schermer; David Walker; G Lozano-Ortega; Basia Rogula; Alison Deighton; Edward Vonesh; Noll Campbell
Journal:  BMJ Open       Date:  2019-05-05       Impact factor: 2.692

2.  OnabotulinumtoxinA is a well tolerated and effective treatment for refractory overactive bladder in real-world practice.

Authors:  Rizwan Hamid; Maria-Fernanda Lorenzo-Gomez; Heinrich Schulte-Baukloh; Amin Boroujerdi; Anand Patel; Elisabeth Farrelly
Journal:  Int Urogynecol J       Date:  2020-07-27       Impact factor: 2.894

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.